Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07467018 · ClinicalTrials.gov registry record
Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County
A clinical trial, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- 100
- Enrollment target
NCT07467018: Recruiting study, sponsored by University of California, Los Angeles.
NCT07467018 is a clinical trial that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07467018 is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
Study Summary
This project evaluates the implementation strategy of the delivery of lenacapavir pre-exposure prophylaxis (LEN PrEP) - a newly available long-acting, injectable medication for human immunodeficiency virus (HIV) prevention - via a mobile health van model for people who are unstably housed in Los Angeles County (LAC). People who are unhoused or are facing housing instability experience significant barriers to accessing HIV prevention care in traditional clinic settings. In 2022, approximately 13% of newly diagnosed HIV cases in LAC were experiencing homelessness, a 36% increase over the prior period. The study will work with the University of California, Los Angeles (UCLA) Health's Homeless Healthcare Collaborative (HHC), which operates mobile health vans staffed by clinicians, social workers, and community health workers, to bring LEN PrEP directly to community settings, such as shelters, encampments, community centers, and transitional housing facilities. This study has three primary aims: 1. Characterize uptake of LEN PrEP among unstably housed people in LAC receiving health services via HHC's mobile program. 2. Evaluate how many study participants stay on LEN PrEP through 52 weeks. 3. Understand costs, acceptability, and sustainability of the mobile LEN PrEP delivery model.
Primary Outcome
The primary outcome will be defined as receiving a first injection of LEN (along with both oral doses on days 1 and 2).
Interventions
- DRUG Lenacapavir
- OTHER Community-based healthcare delivery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-04-21 |
| Est. Completion | 2027-12-31 |
What NCT07467018 shows while recruiting
NCT07467018 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Lenacapavir is the first listed.
NCT07467018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07467018 about?
NCT07467018 is a clinical study titled "Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County". This project evaluates the implementation strategy of the delivery of lenacapavir pre-exposure prophylaxis (LEN PrEP) - a newly available long-acting, injectable medication for human immunodeficiency virus (HIV) prevention - via a mobile health van model for people who are unstably housed in Los Ang...
What is the current status of trial NCT07467018?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2026-04-21. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07467018?
The interventions under investigation include: Lenacapavir (DRUG), Community-based healthcare delivery (OTHER).
Who is sponsoring clinical trial NCT07467018?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI